ACM
OCUL icon

Altium Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Altium Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-517,133
Closed -$2.15M – 121
2022
Q3 		$2.15M Sell
517,133
-177,867
-26% -$896K 0.79% 50
2022
Q2 		$2.79M Hold
695,000
– – 1.12% 33
2022
Q1 		$3.44M Hold
695,000
– – 1.15% 36
2021
Q4 		$4.84M Buy
695,000
+139,000
+25% +$1.08M 1.34% 27
2021
Q3 		$5.56M Buy
556,000
+299,848
+117% +$3.37M 1.46% 21
2021
Q2 		$3.63M Sell
256,152
-70,022
-21% -$1.06M 0.84% 44
2021
Q1 		$5.31M Buy
326,174
+23,000
+8% +$443K 1.47% 17
2020
Q4 		$6.28M Buy
+303,174
New +$4.5M 2.34% 3

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Altium Capital Management's OCUL Position: Q4 2022 in Review

Altium Capital Management sold out of Ocular Therapeutix (OCUL) in Q4 2022, closing a stake of 517,133 shares — an estimated $2.15M sold.

Altium Capital Management first reported a position in OCUL in Q4 2020 and held it in 8 quarters. The position peaked at $6.28M in Q4 2020. 116 funds tracked by Wall St. Rank hold OCUL as of Q4 2022.

  • Altium Capital Management reported no remaining Ocular Therapeutix position as of Q4 2022 after selling out during the quarter.
  • Altium Capital Management sold 517,133 Ocular Therapeutix shares in Q4 2022, an estimated $2.15M.
  • Altium Capital Management first reported a position in Ocular Therapeutix in Q4 2020 and held it in 8 quarters.
  • Altium Capital Management's Ocular Therapeutix position peaked at $6.28M in Q4 2020.
  • 116 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2022.

Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.